https://dev.knoafoundation.org/publication/ 2025-12-02T18:04:58+00:00 https://dev.knoafoundation.org/publication/in-vitro-pharmacological-evaluation-of-the-novel-nop-receptor-partial-agonist-sunobinop/ 2025-10-07T17:29:44+00:00 https://dev.knoafoundation.org/publication/safety-tolerability-and-pharmacokinetics-of-single-and-multiple-ascending-doses-of-sunobinop-in-healthy-participants/ 2025-10-07T17:32:32+00:00 https://dev.knoafoundation.org/publication/evaluation-of-sunobinop-for-next-day-residual-effects-in-healthy-participants/ 2025-10-07T17:34:06+00:00 https://dev.knoafoundation.org/publication/activation-of-nociceptin-orphanin-fq-peptide-nop-receptors-produces-an-increase-in-non-rem-sleep-in-rats-and-constitutes-a-novel-and-attractive-target-for-the-treatment-of-insomnia/ 2025-10-07T17:36:57+00:00 https://dev.knoafoundation.org/publication/evaluation-of-the-human-abuse-potential-of-single-oral-doses-of-v117957-a-novel-highly-potent-and-selective-partial-agonist-for-nociceptin-orphanin-fq-peptide-nop-receptors/ 2025-10-07T17:38:20+00:00 https://dev.knoafoundation.org/publication/the-nociceptin-orphanin-fq-receptor-partial-agonist-sunobinop-promotes-non-rem-sleep-in-rodents-and-patients-with-insomnia/ 2025-10-07T17:41:58+00:00 https://dev.knoafoundation.org/publication/effects-of-sunobinop-v117957-in-a-model-of-acute-cystitis-induced-by-cyclophosphamide/ 2025-10-07T17:43:48+00:00 https://dev.knoafoundation.org/publication/medical-claims-data-analysis-of-comorbidities-in-patients-with-interstitial-cystitis-bladder-pain-syndrome/ 2025-10-07T17:45:31+00:00 https://dev.knoafoundation.org/publication/efficacy-and-safety-of-a-selective-partial-agonist-for-nociception-orphanin-fq-peptide-nop-receptors-in-patients-with-insomnia-disorder/ 2025-10-14T21:12:09+00:00 https://dev.knoafoundation.org/publication/safety-tolerability-and-efficacy-of-a-novel-highly-potent-and-selective-partial-agonist-for-nociceptin-orphanin-fq-peptide-nop-receptors-in-patients-with-insomnia-disorder/ 2025-10-14T21:17:28+00:00 https://dev.knoafoundation.org/publication/current-and-potential-pharmacological-treatment-options-for-insomnia-in-patients-with-alcohol-use-disorder-in-recovery/ 2025-10-14T21:24:29+00:00 https://dev.knoafoundation.org/publication/return-to-alcohol-use-among-patients-who-are-in-recovery-from-alcohol-use-disorder-with-pharmacologically-treated-vs-untreated-insomnia/ 2025-10-14T21:25:04+00:00 https://dev.knoafoundation.org/publication/fusion-therapy-a-new-approach-to-combining-treatments-drug-discovery-world/ 2025-10-14T21:32:18+00:00 https://dev.knoafoundation.org/publication/chemotherapy-is-getting-smarter/ 2025-10-14T21:34:29+00:00 https://dev.knoafoundation.org/publication/the-alkylating-hdac-inhibition-fusion-principle-taking-chemotherapy-to-the-next-level-with-the-first-in-class-molecule-edo-s101/ 2025-10-14T21:34:48+00:00 https://dev.knoafoundation.org/publication/activity-of-the-alkylating-histone-deacetylase-inhibition-fusion-molecule-edo-s-101-in-preclinical-models-of-human-glioblastoma-independent-from-mgmt-expression/ 2025-10-14T21:42:46+00:00 https://dev.knoafoundation.org/publication/the-first-in-class-alkylating-deacetylase-inhibitor-molecule-tinostamustine-shows-antitumor-effects-and-is-synergistic-with-radiotherapy-in-preclinical-models-of-glioblastoma/ 2025-10-14T21:47:37+00:00 https://dev.knoafoundation.org/publication/is-there-hope-to-treat-glioblastoma-effectively/ 2025-10-14T21:48:42+00:00 https://dev.knoafoundation.org/publication/psychomotor-cognitive-effects-pharmacokinetics-and-safety-of-v117957-a-novel-highly-potent-and-selective-partial-agonist-for-nociceptin-orphanin-fq-peptide-nop-receptors-administered-in-combinat/ 2025-10-15T13:25:54+00:00 https://dev.knoafoundation.org/publication/results-from-the-cohort-expansion-stage-of-a-phase-i-trial-of-tinostamustine-monotherapy-in-advanced-haematological-malignancies-nct02576496-findings-from-a-subset-of-patients-with-cutaneous-t-cell/ 2025-10-15T13:36:55+00:00 https://dev.knoafoundation.org/publication/results-from-the-cohort-expansion-stage-of-a-phase-i-trial-of-tinostamustine-monotherapy-in-advanced-hodgkin-lymphoma-hl-non-hodgkin-lymphoma-nhl-and-multiple-myeloma-mm-nct02576496/ 2025-10-15T13:38:39+00:00 https://dev.knoafoundation.org/publication/safety-and-efficacy-of-tinostamustine-in-pre-treated-patients-with-relapsed-refractory-r-r-hodgkin-lymphoma-hl-early-results-from-an-additional-expansion-cohort-of-a-phase-i-study/ 2025-10-15T13:39:48+00:00 https://dev.knoafoundation.org/publication/safety-and-efficacy-of-tinostamustine-in-heavily-pre-treated-patients-with-relapsed-refractory-r-r-hodgkin-lymphoma-hl/ 2025-10-15T13:40:55+00:00 https://dev.knoafoundation.org/publication/the-alkylating-histone-deacetylase-inhibitor-fusion-molecule-edo-s1010-displays-full-bi-functional-properties-in-preclinical-models-of-hematologic-malignancies/ 2025-10-15T13:42:03+00:00 https://dev.knoafoundation.org/publication/edo-s101-a-new-alkylating-histone-deacetylase-inhibitor-hdaci-fusion-molecule-has-superior-activity-against-multiple-myeloma-and-b-cell-lymphoma-and-strong-synergy-with-proteasome-inhibitors-in-vi/ 2025-10-15T13:44:05+00:00 https://dev.knoafoundation.org/publication/safety-and-efficacy-of-tinostamustine-in-a-subpopulation-of-patients-with-relapsed-refractory-hodgkins-lymphoma-phase-1-study/ 2025-10-15T13:56:18+00:00 https://dev.knoafoundation.org/publication/establishment-and-characterization-of-a-reliable-xenograft-model-of-hodgkin-lymphoma-suitable-for-the-study-of-tumor-origin-and-the-design-of-new-therapies/ 2025-10-15T13:58:24+00:00 https://dev.knoafoundation.org/publication/identification-of-novel-therapeutic-targets-in-the-clinically-predictive-vkmyc-mouse-model-of-multiple-myeloma/ 2025-10-15T13:59:11+00:00 https://dev.knoafoundation.org/publication/the-alkylating-histone-deacetylase-inhibitor-fusion-molecule-edo-s101-displays-full-bi-functional-properties-in-preclinical-models-of-hematological-malignancies/ 2025-10-15T14:02:07+00:00 https://dev.knoafoundation.org/publication/edo-s101-a-new-alkylating-histone-deacetylase-inhibitor-hdaci-fusion-molecule-has-superior-activity-against-multiple-myeloma-and-b-cell-lymphoma-and-strong-synergy-with-proteasome-inhibitors-in-vi-2/ 2025-10-15T14:03:45+00:00 https://dev.knoafoundation.org/publication/preclinical-antimyeloma-activity-of-edo-s101-clinical-lymphoma-myeloma-and-leukemia/ 2025-10-15T14:06:35+00:00 https://dev.knoafoundation.org/publication/tinostamustine-edo-s101-an-alkylator-and-histone-deacetylase-inhibitor-enhances-the-efficacy-of-daratumumab-in-multiple-myeloma-by-upregulation-of-cd38-and-nkg2d-ligands/ 2025-10-15T14:10:17+00:00 https://dev.knoafoundation.org/publication/effect-and-mechanism-of-nl-101-combined-with-bcl-2-inhibitor-venetoclax-in-acute-myeloid-leukemia/ 2025-10-15T14:11:52+00:00 https://dev.knoafoundation.org/publication/nl101-synergizes-with-the-bcl-2-inhibitor-venetoclax-through-pi3k-dependent-suppression-of-c-myc-in-acute-myeloid-leukaemia/ 2025-10-15T14:17:39+00:00 https://dev.knoafoundation.org/publication/reinstated-p53-response-and-high-anti-t-cell-leukemia-activity-by-the-novel-alkylating-deacetylase-inhibitor-tinostamustine/ 2025-10-15T14:20:20+00:00 https://dev.knoafoundation.org/publication/a-novel-alkylating-deacetylase-inhibitor-molecule-edo-s101-in-combination-with-cytarabine-synergistically-enhances-apoptosis-of-acute-myeloid-leukemia-cells/ 2025-10-15T14:21:29+00:00 https://dev.knoafoundation.org/publication/high-parp-1-expression-predicts-poor-survival-in-acute-myeloid-leukemia-and-parp-1-inhibitor-and-saha-bendamustine-hybrid-inhibitor-combination-treatment-synergistically-enhances-anti-tumor-effects/ 2025-10-15T14:23:07+00:00 https://dev.knoafoundation.org/publication/a-novel-saha-bendamustine-hybrid-induces-apoptosis-of-leukemia-cells/ 2025-10-15T14:24:41+00:00 https://dev.knoafoundation.org/publication/results-from-a-phase-i-ii-trial-of-tinostamustine-monotherapy-in-advanced-solid-tumors-nct03345485-safety-and-efficacy-in-a-subset-of-patients-with-advanced-ovarian-cancer-ovca/ 2025-10-15T14:28:34+00:00 https://dev.knoafoundation.org/publication/results-from-a-phase-i-ii-trial-of-tinostamustine-monotherapy-in-advanced-solid-tumours-nct03345485-safety-and-efficacy-in-a-subset-of-patients-pts-with-soft-tissue-sarcoma-sts/ 2025-10-15T14:30:51+00:00 https://dev.knoafoundation.org/publication/synergistic-inhibition-of-tumor-growth-and-overcoming-chemo-resistance-simultaneously-targeting-key-components-of-in-dna-damage-repair-epigenetic-putative-cancer-cell-signaling-pathways-using-novel/ 2025-10-15T14:55:47+00:00 https://dev.knoafoundation.org/publication/combination-therapy-with-checkpoint-inhibitors-and-histone-deacetylase-inhibitors-or-alkylating-agents/ 2025-10-15T19:08:03+00:00 https://dev.knoafoundation.org/publication/results-from-a-phase-2-randomized-double-blind-multi-center-placebo-controlled-parallel-group-study-of-sunobinop-in-subjects-who-are-experiencing-insomnia-during-recovery-from-alcohol-use-disorde/ 2025-12-02T17:54:19+00:00 https://dev.knoafoundation.org/publication/the-first-in-class-alkylator%e2%80%91histone%e2%80%91deacetylase%e2%80%91inhibitor-fusion-molecule-edo%e2%80%91s101-in-combination-with-proteasome-inhibitors-induces-highly-synergistic-pro%e2%80%91ap/ 2025-12-02T17:57:01+00:00 https://dev.knoafoundation.org/publication/novel-saha%e2%80%91bendamustine-hybrid-nl%e2%80%91101-in-combination-with-daunorubicin-synergistically-suppresses-acute-myeloid-leukemia/ 2025-12-02T17:58:05+00:00 https://dev.knoafoundation.org/publication/a-phase-i-study-of-tinostamustine-in-patients-pts-with-advanced-solid-tumours-annals-of-oncology/ 2025-12-02T17:59:05+00:00 https://dev.knoafoundation.org/publication/open-label-nonrandomized-phase-ib-study-to-characterize-the-safety-and-recommended-sose-of-tinostamustine-in-combination-with-nivolumab-in-patients-with-advanced-melanoma-enigma/ 2025-12-02T18:01:51+00:00 https://dev.knoafoundation.org/publication/alkylating-histone-deacetylase-inhibitors-may-have-therapeutic-value-in-experimental-myeloperoxidase-anca-vasculitis/ 2025-12-02T18:02:28+00:00 https://dev.knoafoundation.org/publication/a-phase-1-study-of-tinostamustine-a-novel-alkylating-deacetylase-inhibitor-as-an-adjunct-treatment-in-newly-diagnosed-mgmt-promoter-unmethylated-glioblastoma/ 2025-12-02T18:04:13+00:00 https://dev.knoafoundation.org/publication/correction-to-the-first-in-class-alkylating-deacetylase-inhibitor-molecule-tinostamustine-shows-antitumor-effects-and-is-synergistic-with-radiotherapy-in-preclinical-models-of-glioblastoma/ 2025-12-02T18:04:46+00:00 https://dev.knoafoundation.org/publication/combined-alkylation-and-histone-deacetylase-inhibition-with-edo-s101-has-significant-therapeutic-activity-against-brain-tumors-in-preclinical-models/ 2025-12-02T18:04:58+00:00